Does the media prefer DWTX or ACOG?

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 4 articles in the media. Dogwood Therapeutics' average media sentiment score of 0.72 beat Alpha Cognition's score of 0.54 indicating that Dogwood Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Cognition 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ZNTL or DWTX more profitable?

Zentalis Pharmaceuticals' return on equity of -70.18% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zentalis Pharmaceuticals N/A -70.18% -51.46% Dogwood Therapeutics N/A -75.55% -40.28%

Does the media favor ZNTL or DWTX?

In the previous week, Zentalis Pharmaceuticals had 6 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 10 mentions for Zentalis Pharmaceuticals and 4 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.72 beat Zentalis Pharmaceuticals' score of 0.45 indicating that Dogwood Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zentalis Pharmaceuticals 1 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, DWTX or ANTX?

Anthem is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dogwood Therapeutics N/A N/A -$34.26M -$8.95 N/A Anthem N/A N/A -$35.17M -$1.07 N/A

Is DWTX or ANTX more profitable?

Anthem's return on equity of -53.52% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dogwood Therapeutics N/A -75.55% -40.28% Anthem N/A -53.52% -48.63%

Does the media prefer DERM or DWTX?

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Journey Medical. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 3 mentions for Journey Medical. Dogwood Therapeutics' average media sentiment score of 0.72 beat Journey Medical's score of 0.66 indicating that Dogwood Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Journey Medical 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, NERV or DWTX?

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$28.87 N/A Dogwood Therapeutics N/A N/A -$34.26M -$8.95 N/A

Is NERV or DWTX more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Dogwood Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Dogwood Therapeutics N/A -75.55% -40.28%

Does the media prefer NERV or DWTX?

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.89 beat Dogwood Therapeutics' score of 0.72 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dogwood Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Dogwood Therapeutics (DWTX) Competitors

$1.40 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.47 +0.07 (+4.93%)

As of 05:03 AM Eastern

Compare

DWTX vs. ACOG, ZNTL, ANTX, DERM, and NERV

Should you buy Dogwood Therapeutics stock or one of its competitors? Dogwood Therapeutics's main competitors and comparable companies include Alpha Cognition (ACOG), Zentalis Pharmaceuticals (ZNTL), Anthem (ANTX), Journey Medical (DERM), and Minerva Neurosciences (NERV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Dogwood Therapeutics compare to Alpha Cognition?

Dogwood Therapeutics (NASDAQ:DWTX) and Alpha Cognition (NASDAQ:ACOG) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Dogwood Therapeutics has a net margin of 0.00% compared to Alpha Cognition's net margin of -153.61%. Alpha Cognition's return on equity of -54.60% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Alpha Cognition	-153.61%	-54.60%	-43.47%

In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 4 articles in the media. Dogwood Therapeutics' average media sentiment score of 0.72 beat Alpha Cognition's score of 0.54 indicating that Dogwood Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Cognition	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Cognition has higher revenue and earnings than Dogwood Therapeutics. Alpha Cognition is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Alpha Cognition	$10.22M	19.27	-$20.67M	-$1.10	N/A

Dogwood Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Alpha Cognition has a beta of 2.32, meaning that its stock price is 132% more volatile than the broader market.

9.1% of Dogwood Therapeutics shares are held by institutional investors. 0.3% of Dogwood Therapeutics shares are held by insiders. Comparatively, 8.6% of Alpha Cognition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Dogwood Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 757.14%. Alpha Cognition has a consensus price target of $18.00, indicating a potential upside of 99.12%. Given Dogwood Therapeutics' higher probable upside, research analysts clearly believe Dogwood Therapeutics is more favorable than Alpha Cognition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alpha Cognition	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Alpha Cognition beats Dogwood Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Zentalis Pharmaceuticals has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

Dogwood Therapeutics has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Zentalis Pharmaceuticals is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zentalis Pharmaceuticals	$67.43M	2.81	-$137.06M	-$1.95	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

9.1% of Dogwood Therapeutics shares are held by institutional investors. 3.8% of Zentalis Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Zentalis Pharmaceuticals' return on equity of -70.18% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Zentalis Pharmaceuticals presently has a consensus target price of $7.50, suggesting a potential upside of 184.09%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 757.14%. Given Dogwood Therapeutics' higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Zentalis Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zentalis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Zentalis Pharmaceuticals had 6 more articles in the media than Dogwood Therapeutics. MarketBeat recorded 10 mentions for Zentalis Pharmaceuticals and 4 mentions for Dogwood Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.72 beat Zentalis Pharmaceuticals' score of 0.45 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zentalis Pharmaceuticals	1 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zentalis Pharmaceuticals beats Dogwood Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Anthem?

Dogwood Therapeutics (NASDAQ:DWTX) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Anthem is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 0.3% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Anthem's return on equity of -53.52% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-75.55%	-40.28%
Anthem	N/A	-53.52%	-48.63%

In the previous week, Dogwood Therapeutics had 3 more articles in the media than Anthem. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 1 mentions for Anthem. Anthem's average media sentiment score of 1.82 beat Dogwood Therapeutics' score of 0.72 indicating that Anthem is being referred to more favorably in the news media.

Company	Overall Sentiment
Dogwood Therapeutics	Positive
Anthem	Very Positive

Dogwood Therapeutics currently has a consensus target price of $12.00, suggesting a potential upside of 757.14%. Anthem has a consensus target price of $9.00, suggesting a potential upside of 104.55%. Given Dogwood Therapeutics' higher probable upside, research analysts clearly believe Dogwood Therapeutics is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dogwood Therapeutics has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

Summary

Anthem beats Dogwood Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Journey Medical?

Journey Medical (NASDAQ:DERM) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

7.3% of Journey Medical shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 14.5% of Journey Medical shares are owned by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Journey Medical currently has a consensus price target of $14.00, indicating a potential upside of 121.87%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 757.14%. Given Dogwood Therapeutics' higher probable upside, analysts plainly believe Dogwood Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dogwood Therapeutics had 1 more articles in the media than Journey Medical. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 3 mentions for Journey Medical. Dogwood Therapeutics' average media sentiment score of 0.72 beat Journey Medical's score of 0.66 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Journey Medical	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dogwood Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Journey Medical	-8.95%	-20.23%	-6.60%
Dogwood Therapeutics	N/A	-75.55%	-40.28%

Journey Medical has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Journey Medical has higher revenue and earnings than Dogwood Therapeutics. Journey Medical is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Journey Medical	$61.86M	2.88	-$11.43M	-$0.22	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

Summary

Journey Medical beats Dogwood Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Dogwood Therapeutics compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Minerva Neurosciences' return on equity of 0.00% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Dogwood Therapeutics	N/A	-75.55%	-40.28%

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 0.3% of Dogwood Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Dogwood Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$8.95	N/A

Minerva Neurosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market.

Minerva Neurosciences currently has a consensus price target of $10.33, indicating a potential upside of 224.95%. Dogwood Therapeutics has a consensus price target of $12.00, indicating a potential upside of 757.14%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dogwood Therapeutics had 2 more articles in the media than Minerva Neurosciences. MarketBeat recorded 4 mentions for Dogwood Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.89 beat Dogwood Therapeutics' score of 0.72 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dogwood Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Minerva Neurosciences and Dogwood Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Dogwood Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DWTX vs. The Competition

Export

Metric	Dogwood Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$47.59M	$12.39B	$7.25B	$13.28B
Dividend Yield	N/A	2.63%	2.52%	22.58%
P/E Ratio	-0.16	800.13	275.59	26.13
Price / Sales	N/A	786.06	595.29	89.84
Price / Cash	N/A	15.28	27.30	36.12
Price / Book	0.60	9.07	10.58	6.16
Net Income	-$34.26M	$2.84B	$3.50B	$381.12M
7 Day Performance	-7.89%	-0.95%	-1.21%	-1.43%
1 Month Performance	-27.84%	-3.73%	-4.02%	-3.36%
1 Year Performance	-73.93%	-4.05%	7.17%	1.49%

Dogwood Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DWTX Dogwood Therapeutics	3.312 of 5 stars	$1.40 flat	$12.00 +757.1%	-73.9%	$47.59M	N/A	N/A	8	Short Interest Decrease Gap Up
ACOG Alpha Cognition	3.6656 of 5 stars	$9.13 +1.6%	$18.00 +97.2%	+28.8%	$198.75M	$15.26M	N/A	71	Short Interest Increase
ZNTL Zentalis Pharmaceuticals	3.3137 of 5 stars	$2.67 -0.2%	$7.50 +181.4%	+57.1%	$191.72M	$67.43M	N/A	106
ANTX Anthem	2.3219 of 5 stars	$5.00 -1.4%	$9.00 +80.0%	+246.5%	$188.81M	N/A	N/A	N/A	Positive News Gap Up
DERM Journey Medical	1.6363 of 5 stars	$6.13 -0.6%	$14.00 +128.6%	-12.5%	$172.85M	$61.86M	N/A	58

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DWTX) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. ACOG, ZNTL, ANTX, DERM, and NERV

How does Dogwood Therapeutics compare to Alpha Cognition?

Summary

How does Dogwood Therapeutics compare to Zentalis Pharmaceuticals?

Summary

How does Dogwood Therapeutics compare to Anthem?

Summary

How does Dogwood Therapeutics compare to Journey Medical?

Summary

How does Dogwood Therapeutics compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dogwood Therapeutics (DWTX) Competitors

DWTX vs. ACOG, ZNTL, ANTX, DERM, and NERV

How does Dogwood Therapeutics compare to Alpha Cognition?

Is DWTX or ACOG more profitable?

Does the media prefer DWTX or ACOG?

Which has better earnings and valuation, DWTX or ACOG?

Which has more volatility & risk, DWTX or ACOG?

Do institutionals and insiders hold more shares of DWTX or ACOG?

Do analysts rate DWTX or ACOG?

Summary

How does Dogwood Therapeutics compare to Zentalis Pharmaceuticals?

Which has more risk and volatility, ZNTL or DWTX?

Which has stronger valuation and earnings, ZNTL or DWTX?

Do institutionals & insiders have more ownership in ZNTL or DWTX?

Is ZNTL or DWTX more profitable?

Do analysts recommend ZNTL or DWTX?

Does the media favor ZNTL or DWTX?

Summary

How does Dogwood Therapeutics compare to Anthem?

Which has preferable earnings & valuation, DWTX or ANTX?

Do insiders and institutionals hold more shares of DWTX or ANTX?

Is DWTX or ANTX more profitable?

Does the media refer more to DWTX or ANTX?

Do analysts rate DWTX or ANTX?

Which has more volatility and risk, DWTX or ANTX?

Summary

How does Dogwood Therapeutics compare to Journey Medical?

Do institutionals and insiders believe in DERM or DWTX?

Do analysts recommend DERM or DWTX?

Does the media prefer DERM or DWTX?

Is DERM or DWTX more profitable?

Which has more volatility & risk, DERM or DWTX?

Which has stronger valuation and earnings, DERM or DWTX?

Summary

How does Dogwood Therapeutics compare to Minerva Neurosciences?

Is NERV or DWTX more profitable?

Do insiders & institutionals believe in NERV or DWTX?

Which has better valuation and earnings, NERV or DWTX?

Which has more risk and volatility, NERV or DWTX?

Do analysts rate NERV or DWTX?

Does the media prefer NERV or DWTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DWTX vs. The Competition

Dogwood Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools